Revolution Medicines, INC Form 4 insider transactions

Revolution Medicines, Inc. Director Flavia Borellini reported the acquisition of 3,142 restricted stock units and 11,574 stock options on June 26, 2025, as part of her compensation.

Revolution Medicines, Inc. Director Elizabeth M. Anderson acquired 3,142 Restricted Stock Units and 11,574 stock options on June 26, 2025, increasing her beneficial ownership in the company.

Revolution Medicines, Inc. Director Frank Clyburn reported the acquisition of 2,806 shares of common stock and 10,337 stock options on June 26, 2025, increasing his beneficial ownership in the company.

Jeff Cislini, General Counsel of Revolution Medicines, Inc., sold 1,912 shares of common stock for approximately $75,760 under a pre-arranged 10b5-1 trading plan.

Revolution Medicines, Inc.'s Chief Operating Officer, Margaret A. Horn, sold 3,510 shares of common stock on June 16, 2025, at a weighted average price of $39.83, to cover tax withholding obligations related to RSU vesting.

Revolution Medicines, Inc. CEO Mark A. Goldsmith sold 13,496 shares of common stock for $39.83 per share on June 16, 2025, to cover tax withholding obligations related to restricted stock unit vesting.

Revolution Medicines, Inc.'s General Counsel, Jeff Cislini, sold 1,878 shares of common stock for approximately $39.83 per share to cover tax withholding obligations related to RSU vesting, as disclosed in a recent SEC Form 4 filing.

Revolution Medicines, Inc. Chief Financial Officer, Jack Anders, sold 2,170 shares of common stock on June 16, 2025, at a weighted average price of $39.83 per share, primarily to satisfy tax withholding obligations related to restricted stock unit vesting.

Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, Inc., sold 4,289 shares of common stock to cover tax withholding obligations related to RSU vesting.

Revolution Medicines' Chief Medical Officer, Wei Lin, sold 2,173 shares of common stock on June 16, 2025, at a weighted average price of $39.83 per share, as part of a pre-arranged Rule 10b5-1 plan to cover tax withholding from RSU vesting.

Frank Clyburn, a director at Revolution Medicines, files an amendment to a previous Form 4 to correct the amount of a stock option award granted on August 5, 2024.

Jeff Cislini, General Counsel of Revolution Medicines, sold 2,041 shares of common stock on March 20, 2025, under a pre-arranged 10b5-1 trading plan.

Jeff Cislini, General Counsel of Revolution Medicines, sold 1,458 shares of common stock on March 17, 2025, to cover tax obligations related to vesting restricted stock units.

Mark A. Goldsmith, CEO of Revolution Medicines, sold 11,738 shares of common stock on March 17, 2025, to cover tax obligations related to vesting restricted stock units.

Chief Financial Officer of Revolution Medicines, Jack Anders, sold 1,864 shares of common stock on March 17, 2025, to cover tax obligations related to vesting restricted stock units.

Margaret Horn, Chief Operating Officer of Revolution Medicines, sold 3,058 shares of common stock on March 17, 2025, to cover tax obligations related to vesting restricted stock units.

Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, sold 3,294 shares of common stock on March 17, 2025, to cover tax obligations related to vesting restricted stock units.

Xiaolin Wang, EVP of Clinical Development at Revolution Medicines, reported a gift of 2,718 shares of common stock on March 17, 2025, leaving them with 102,321 shares.

Jeff Cislini, General Counsel of Revolution Medicines, reports the acquisition of 22,000 shares of common stock and 77,000 stock options.

Chief Financial Officer of Revolution Medicines, Jack Anders, reports the acquisition of stock options and restricted stock units (RSUs) in the company.

Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, acquired shares and stock options on March 1, 2025.

Margaret Horn, Chief Operating Officer of Revolution Medicines, reports acquiring 28,600 shares of common stock and 100,100 stock options on March 1, 2025.

Chief Medical Officer of Revolution Medicines, Wei Lin, reports the acquisition of stock options and disposal of common stock related to restricted stock units.

Xiaolin Wang, an officer at Revolution Medicines, reports acquiring 19,000 shares of common stock and 66,500 stock options.

Mark A. Goldsmith, CEO of Revolution Medicines, reports acquisition of shares and options, including restricted stock units and stock options, as per a recent SEC filing.

Revolution Medicines' General Counsel, Jeff Cislini, sold 2,406 shares of common stock at $40.5 per share under a pre-arranged 10b5-1 trading plan.

Mark A. Goldsmith, President and CEO of Revolution Medicines, executed stock options and reported changes in beneficial ownership of company stock.

Margaret Horn, Chief Operating Officer of Revolution Medicines, sold 4,329 shares of common stock on December 16, 2024, to cover tax obligations related to vesting restricted stock units.

Mark A. Goldsmith, CEO of Revolution Medicines, sold 11,714 shares of common stock on December 16, 2024, to cover tax obligations related to vesting restricted stock units.

Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, sold 4,663 shares of common stock on December 16, 2024, to cover tax obligations related to vesting restricted stock units.